T

Texas Retina Associates | Dallas. TX

Research site
(Unclaimed)
Location
9600 North Central Expressway, Suite 100, Dallas, Texas, United States of America

Site insights

Top conditions

Top treatments

OPL-0401
AU-011
AVD-104
Pegcetacoplan
JNJ-81201887
Vamikibart

Parent organization

This site is a part of Texas Retina Associates

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 6 total trials

A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) (SIGLEC)

Investigate the Safety, Pharmacokinetics, and Treatment effects of Single and Multi-dose of Intravitreal AVD-104 in participants with geographic atro...

Enrolling
Macular Degeneration
Geographic Atrophy of the Macula
Drug: AVD-104
Drug: Avacincaptad

The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary i...

Enrolling
Indeterminate Lesions
Ocular Melanoma
Device: Suprachoroidal Microinjector
Drug: Sham Treatment

The purpose of this study is to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control.

Enrolling
Geographic Atrophy
Drug: Triamcinolone
Other: Sham Procedure

This study will assess the efficacy and safety of vamikibart in participants with uveitic macular edema.

Enrolling
Uveitic Macular Edema
Other: Sham
Drug: Vamikibart

OPL-0401-201 is a multicenter study to investigate the safety and efficacy of OPL-0401 in patients with diabetes mellitus (DM) with diabetic retinopa...

Active, not recruiting
Non-proliferative Diabetic Retinopathy
Proliferative Diabetic Retinopathy
Drug: Placebo
Drug: OPL-0401 Dose 1

Trial sponsors

A
Aura Biosciences logo
A
Janssen (J&J Innovative Medicine) logo
Roche logo
V

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems